References
1. Craig, W.A., Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men. Clinical Infectious Diseases, 1998. 26 (1): p. 1-12.
2. Blot, S.I., F. Pea, and J. Lipman, The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents. Advanced Drug Delivery Reviews, 2014. 77 : p. 3-11.
3. Briscoe, S.E., et al., A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. Journal of Chromatography B, 2012. 907 : p. 178-184.
4. Colman, S., et al., Measuring Unbound Versus Total Piperacillin Concentrations in Plasma of Critically Ill Patients: Methodological Issues and Relevance. Ther Drug Monit, 2019. 41 (3): p. 325-330.
5. Wong, G., et al., Protein Binding of B-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations? 2013. 57 (12): p. 6165-6170.
6. Al-Shaer, M.H., et al., Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples. Ther Drug Monit, 2020.42 (1): p. 129-132.
7. Roberts, D.M., et al., A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Critical Care, 2015. 19 (1): p. 84.
8. Ulldemolins, M., et al., Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. J Antimicrob Chemother, 2016. 71 (6): p. 1651-9.
9. Hayashi, Y., et al., Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opinion on Drug Metabolism & Toxicology, 2010. 6 (8): p. 1017-1031.
10. El-Haffaf, I., et al., Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients. Clinical Pharmacokinetics, 2022.
11. Klastrup, V., et al., Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment. Antimicrob Agents Chemother, 2020. 64 (7).
12. Roberts, J.A., F. Pea, and J. Lipman, The clinical relevance of plasma protein binding changes. Clin Pharmacokinet, 2013.52 (1): p. 1-8.
13. Al-Shaer, M.H., et al., Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples. 2020. 42 (1): p. 129-132.
14. Colman, S., et al., Measuring Unbound Versus Total Piperacillin Concentrations in Plasma of Critically Ill Patients: Methodological Issues and Relevance. 2019. 41 (3): p. 325-330.
15. Klastrup, V., et al., Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment. Antimicrobial Agents and Chemotherapy, 2020. 64 (7): p. e02556-19.
16. Guang, W., M. Baraldo, and M. Furlanut, Calculating percentage prediction error: A user’s note. Pharmacological Research, 1995.32 (4): p. 241-248.
17. Varvel, J.R., D.L. Donoho, and S.L. Shafer, Measuring the predictive performance of computer-controlled infusion pumps. Journal of Pharmacokinetics and Biopharmaceutics, 1992. 20 (1): p. 63-94.
18. Ulldemolins, M., et al., The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet, 2011. 50 (2): p. 99-110.
19. Chen, I.H. and D.P. Nicolau, Augmented Renal Clearance and How to Augment Antibiotic Dosing. Antibiotics (Basel, Switzerland), 2020.9 (7): p. 393.
20. El-Haffaf, I., J.-A. Caissy, and A. Marsot,Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses. Clinical Pharmacokinetics, 2021.60 (7): p. 855-875.
21. Felton, T.W., et al., Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother, 2013. 57 (12): p. 5811-9.
22. Sumi, C.D., et al., What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clin Pharmacokinet, 2019. 58 (11): p. 1407-1443.
23. Asín-Prieto, E., et al., Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy, 2013. 69 (1): p. 180-189.